Top Markets
#1 Ontology Gas Ontology Gas +30.80%
#2 EXOD EXOD +22.08%
#3 Status Status +21.90%
#4 ETHGas ETHGas +19.74%
#5 The Black Bull The Black Bull +17.98%
#6 Anvil Anvil +12.83%
#7 Fake World Assets Fake World Assets +10.94%
#8 aelf aelf +9.61%
#9 Gas Gas +9.27%
#10 Derive Derive +8.79%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rank in Stocks #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Share Price
$9.81
Last synced: 2025-03-18
Market Cap
$48.68M
Change (1 day)
1.55%
Change (1 year)
0.00%
Country
US
Trade AlloVir, Inc. (ALVR)

Category

Healthcare
P/B ratio for AlloVir, Inc. (ALVR)
P/B ratio as of August 2026 TTM: 1.68
According to AlloVir, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 1.68. At the end of 2023 the company had a P/B ratio of 0.00.
P/B ratio history for AlloVir, Inc. from 2022 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 1.68 320.88%
2024 0.40 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 276.71%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 270.73%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 48.82%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 120.30%
US